tiprankstipranks
Vericel Corp (VCEL)
NASDAQ:VCEL
US Market
Holding VCEL?
Track your performance easily

Vericel (VCEL) Earnings Dates, Call Summary & Reports

578 Followers

Earnings Data

Report Date
Mar 04, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
0.3
Last Year’s EPS
0.26
Same Quarter Last Year
Based on 7 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 06, 2018
|
% Change Since: 22.96%
|
Next Earnings Date:Aug 06, 2018
Earnings Call Sentiment|Positive
Vericel had a strong third quarter with significant revenue growth, margin expansion, and key regulatory approvals. Despite reporting a net loss and increased operating expenses, the company's financial performance was robust, with strong cash flow and a positive outlook for future growth.
Company Guidance
During Vericel's third-quarter 2024 earnings call, the company reported a 27% year-over-year revenue growth, achieving a record $57.9 million in quarterly revenue, surpassing their guidance. This growth was driven by a 19% increase in MACI revenue, reaching $44.7 million, and a notable 66% increase in Burn Care revenue, totaling $13.2 million. The gross margin expanded to 72% of net revenue, an increase of 480 basis points from the previous year. Operating expenses rose to $44.1 million, primarily due to MACI Arthro's development and launch activities. The net loss narrowed to $0.9 million, or $0.02 per share, compared to a $3.7 million loss in the prior year. Adjusted EBITDA grew by 84% to $10 million, representing 17% of revenue, while operating cash flow exceeded $10 million, leaving the company with $151 million in cash, restricted cash, and investments, and no debt. For the full year, Vericel maintained its revenue guidance of $238 million to $242 million and raised its gross margin and adjusted EBITDA margin guidance to 72% and 22%, respectively.
Record Third Quarter Revenue
Vericel achieved record third quarter revenue of approximately $58 million, a 27% increase compared to the previous year, exceeding their guidance for the quarter.
Significant Margin Expansion
The company reported a gross profit of $41.7 million, or 72% of net revenue, an increase of 480 basis points compared to 2023.
Regulatory Milestones Achieved
Vericel received FDA approval for MACI Arthro and the NexoBrid pediatric indication, positioning the company for future growth.
Strong Burn Care Revenue Growth
Total Burn Care revenue in the third quarter grew 66% to $13.2 million, driven by record quarterly Epicel revenue of $12.2 million.
Positive Adjusted EBITDA Growth
Adjusted EBITDA for the quarter increased 84% to $10 million, or 17% of revenue, an increase of over 500 basis points versus the prior year.
Strong Cash Position
The company generated over $10 million of operating cash flow and ended the third quarter with $151 million in cash, restricted cash, and investments with no debt.
---

Vericel (VCEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

VCEL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 20182018 (Q2)
- / -0.12
-0.07-71.43% (-0.05)
Nov 06, 20182018 (Q3)
- / -0.02
-0.1687.50% (+0.14)
Feb 26, 20192018 (Q4)
- / 0.11
0.011000.00% (+0.10)
May 07, 20192019 (Q1)
- / -0.07
-0.2166.67% (+0.14)
Aug 06, 20192019 (Q2)
- / -0.45
-0.12-275.00% (-0.33)
Nov 05, 20192019 (Q3)
- / 0.07
-0.02450.00% (+0.09)
Feb 25, 20202019 (Q4)
- / 0.20
0.1181.82% (+0.09)
May 05, 20202020 (Q1)
- / -0.10
-0.07-42.86% (-0.03)
Aug 05, 20202020 (Q2)
- / -0.18
-0.4560.00% (+0.27)
Nov 05, 20202020 (Q3)
- / 0.08
0.0714.29% (<+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

VCEL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 07, 2024$48.04$50.03+4.14%
Aug 01, 2024$50.52$47.52-5.94%
May 08, 2024$49.52$47.69-3.70%
Feb 29, 2024$47.80$45.68-4.44%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Vericel Corp (VCEL) report earnings?
Vericel Corp (VCEL) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
    What is Vericel Corp (VCEL) earnings time?
    Vericel Corp (VCEL) earnings time is at Mar 04, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is VCEL EPS forecast?
          VCEL EPS forecast for the fiscal quarter 2024 (Q4) is 0.3.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis